Latest Keryx Biopharmaceuticals Inc. Stories
NEW YORK, June 3, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. Dr. Julia Lewis, Professor of Medicine, Department of...
Keryx to Host Investor Conference Call on Wednesday, May 8, 2013 at 8:30am EDT NEW YORK, May 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2013. At March 31, 2013, the Company had cash and cash equivalents...
Investor Conference Call to be held Wednesday, May 8, 2013 at 8:30am EDT NEW YORK, May 6, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 8, 2013 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2013...
Presentation Scheduled for Monday, March 18th at 10:00 AM PT NEW YORK, March 14, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the upcoming 25th Annual ROTH Conference, to be held March 17(th) -20(th) in Dana Point, California. Mr. Bentsur's presentation is scheduled to take place on Monday, March 18(th), at 10:00 AM PT (1:00 PM ET). A live audio webcast of Mr....
NEW YORK, March 13, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Amit Sharma, M.D. to the newly created position of Vice President, Medical Affairs. Amit Sharma, M.D., is an accomplished board certified nephrologist, internist, and...
Keryx to Host Investor Conference Call Tomorrow, Tuesday, March 12, 2013 at 8:30am EDT NEW YORK, March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2012. At December 31, 2012, the Company had...
Investor Conference Call to be held Tomorrow, Tuesday, March 12, 2013 at 8:30am EDT NEW YORK, March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held tomorrow, Tuesday, March 12, 2013 at 8:30 a.m. EDT to discuss the Company's fourth quarter...
LONDON, February 26, 2013 /PRNewswire/ -- Drug companies work on precarious grounds. Their stock may go up and down based on the future expectations about their drugs. Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) scored new 52-week high despite having no drug in the market. The stock is basically moving up on the expectation of its drug candidate receiving FDA approval. On the other hand, Sanofi (NYSE: SNY) also reached a new high on the strength of its existing and potential...
NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Citigroup 2013 Global Healthcare Conference, being held February 25-27, 2013, in New York City. Mr. Bentsur's presentation is scheduled to take place on Wednesday, February 27(th), at 2:15 PM ET. A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information...
NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NasdaqCM: KERX). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) Keryx and its Chief Executive Officer Ron Bentsur are alleged to have violated Section 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically,...
